Recent advances and future trends in the targeted therapy of metastatic gastric cancer

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 5, 2014, Pages 555-569

  Al Batran, Salah Eddin ^a   Werner, Dominique ^a  

^a KRANKENHAUS NORDWEST   (Germany)

Author keywords

Biological; Esophageal; Esophagogastric; Gastric; Gastroesophageal; Molecular; Oesophageal; Personalized; Targeted; Treatment

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; AURORA KINASE; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; FLUOROPYRIMIDINE; HEAT SHOCK PROTEIN 90; IRINOTECAN; LAPATINIB; MESENCHYMAL EPITHELIAL TRANSITION FACTOR; METALLOPROTEINASE; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PERTUZUMAB; PLACEBO; POLO LIKE KINASE 1; POZIOTINIB; PROSTAGLANDIN SYNTHASE; SOMATOMEDIN C; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ABNORMAL LABORATORY RESULT; ANTIANGIOGENIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARDIOTOXICITY; CELL PROLIFERATION; CELL SURVIVAL; DIARRHEA; DNA REPAIR; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; GENE; GENE FUNCTION; HEADACHE; HER2 GENE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER FUNCTION TEST; LIVER FUNCTION TEST ABNORMALITY; LOWER ESOPHAGUS SPHINCTER; METASTASIS POTENTIAL; MONOTHERAPY; NAIL DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; QT INTERVAL; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREND STUDY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SECONDARY; STOMACH NEOPLASMS; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84903175348     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.902304     Document Type: Review

References (134)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893Y917
2. Grabsch HI, Tan P. Gastric cancer pathology and underlying molecular mechanisms. Dig Surg 2013;30(2):150Y8
3. Tan IB, Ng I, Tai WM, Tan P. Understanding the genetic basis of gastric cancer: Recent advances. Expert Rev Gastroenterol Hepatol 2012;6(3):335Y41
4. Schuell B, Gruenberger T, Scheithauer W. Zielinski Ch, Wrba F. HER2/neu protein expression in colorectal cancer. BMC Cancer 2006;6:123
5. Eltze E, Wülfing C, Von Struensee D, et al. CoxY2 and Her2/neu coYexpression in invasive bladder cancer. Int J Oncol 2005; 26(6):1525Y31
6. McKenzie SJ, DeSombre KA, Bast BS, et al. Serum levels of HERY2 neu (CYerbB) correlate with overexpression of p185(neu) in human ovarian cancer. Cancer 1993; 71(12):3942Y6
7. Grávalos C, GómezYMartín C, Rivera F, et al. Phase II study of trastuzumab. and cisplatin as firstYline therapy in patients with HER2Ypositive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 2011;13(3):179Y84
8. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2Ypositive advanced gastric or gastroYoesophageal junction cancer (ToGA): A phase 3, openYlabel, randomised controlled trial. Lancet 2010;376(9742): 687Y97
9. Verma S, Miles D, Gianni L, et al. EMILIA Study Group. Trastuzumab emtansine for HER2Ypositive advanced breast cancer. N Engl J Med 2012;367(19): 1783Y91
10. Barok M, Tanner M, Köninki K, Isola J. TrastuzumabYDM1 is highly effective in preclinical models of HER2Ypositive gastric cancer. Cancer Lett 2011;306(2):171Y9
11. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumabYDM1 for the treatment of human epidermal growth factor receptor 2 (HER2)Ypositive breast cancer after prior HER2Ydirected therapy. J Clin Oncol 2011;29(4):398Y405
12. ClinicalTrials.gov identifier: NCT01641939. Available from: Http://clinicaltrials.gov/ct2/ show/NCT01641939
13. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2Ypositive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28(7):1138Y44
14. Fuentes G, Scaltriti M, Baselga J, Verma CS. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: An in silico based mechanism. Breast Cancer Res 2011;13(3):R54
15. ClinicalTrials.gov identifier: NCT01461057. Available from: Http://clinicaltrials.gov/ct2/ show/NCT01461057
16. Tabernero J, Hoff PM, Shen L, et al. Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2Ypositive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB). J Clin Oncol 2013;31(Suppl):Abstract TPS4150
17. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109Y19
18. Iqbal S, Goldman B, FenoglioYPreiser CM, et al. Southwest Oncology Group study S0413: A phase II trial of lapatinib (GW572016) as firstYline therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011;22(12):2610Y15
19. Hecht JR, Bang YJ, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2Ypositive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIOY013/LOGiC Trial. J Clin Oncol 2013;31(Suppl):Abstract LBA4001
20. Bang YJ. A randomized, openYlabel, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the secondYline treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population. Tytan study. J Clin Oncol 2012;30(Suppl 34):Abstract 11
21. Wong TW, Lee FY, Yu C, et al. Preclinical antitumor activity of BMSY599626, a panYHER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006; 12(20 Pt 1):6186Y93
22. Nam HJ, Kim HP, Yoon YK. Antitumor activity of HM781Y36B, an irreversible PanYHER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett 2011;302(2):155Y65
23. Nam HJ, Ching KA, Kan J, et al. Evaluation of the antitumor effects and mechanisms of PF00299804, a panYHER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol Cancer Ther 2012;11(2): 439Y51
24. ClinicalTrials.gov identifier: NCT01152853. Available from: Http://clinicaltrials.gov/show/ NCT01152853
25. Liu L, Wu N, Li J. Novel targeted agents for gastric cancer. J Hematol Oncol 2012;5:31
26. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265(14):7709Y12
27. Ferris RL, Jaffee EM, Ferrone S. Tumor antigenYtargeted, monoclonal antibodyYbased immunotherapy: Clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010;28(28):4390Y9
28. Lordick F, Luber B, Lorenzen S, et al. Cetuximab plus oxaliplatin/leucovorin/5Yfluorouracil in firstYline metastatic gastric cancer: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010;102(3): 500Y5
29. Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009; 100(2):298Y304
30. Kim C, Lee JL, Ryu MH, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2011;29(2):366Y73
31. Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastroYoesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009; 101(8):1261Y8
32. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18(3):510Y17
33. Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, openYlabel phase 3 trial. Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. Lancet Oncol 2013;14(6): 490Y9
34. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): A multicentre, phase 2/ 3 randomised trial. Lancet Oncol 2013; 14(7):627Y37
35. Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, openYlabel phase 3 trial. Lancet Oncol 2013;14(6):481Y9
36. Kim YH, Sasaki Y, Lee KH, et al. Randomized phase II study of nimotuzumab, an antiYEGFR antibody, plus irinotecan in patients with 5YfluorouracilYbased regimenYrefractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results. J Clin Oncol 2011;29(Suppl 4):Abstract 87
37. Rao S, Starling N, Cunningham D, et al. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008; 99(6):868Y74
38. Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as firstYline treatment in patients with advanced oesophagoYgastric cancer: A randomised, multicentre openYlabel phase II study. Ann Oncol 2010;21(11):2213Y19
39. Dragovich T, McCoy S, FenoglioYPreiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24(30):4922Y7
40. Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006;24(26):4309Y16
41. Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010;5(2): 229Y35
42. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastroYoesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placeboYcontrolled, phase 3 trial. Lancet 2014;383(9911):31Y9
43. Wilke H, Van Cutsem E, Oh SC, et al. A global, phase III, randomized, doubleYblind study of ramucirumab plus paclitaxel versus placebo plus paclitaxelin the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on firstYline platinumY and fluoropyrimidineYcontaining combination therapy rainbow IMCL CP12Y0922 (I4TYIEYJVBB). J Clin Oncol 2014;32(Suppl 3):Abstract LBA7
44. Uronis HE, Bendell JC, Altomare I, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Oncologist 2013;18(3):271Y2
45. Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29(7): 868Y74
46. ElYRayes BF, Zalupski M, BekaiYSaab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010;21(10):1999Y2004
47. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24(33):5201Y6
48. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as firstYline therapy in advanced gastric cancer: A randomized, doubleYblind, placeboYcontrolled phase III study. J Clin Oncol 2011;29(30):3968Y76
49. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as firstYline therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;30(17): 2119Y27
50. ClinicalTrials.gov identifier: NCT00450203. Available from: Http://clinicaltrials.gov/show/ NCT00450203
51. Li J, Qin S, Xu J, et al. Apatinib for chemotherapyYrefractory advanced metastatic gastric cancer: Results from a randomized, placeboYcontrolled, parallelYarm, phase II trial. J Clin Oncol 2013;31(26):3219Y25
52. ClinicalTrials.gov identifier: NCT01512745. Available from: Http://clinicaltrials.gov/show/ NCT01512745
53. Satoh T, Yamada Y, Muro K, et al. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (SY1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol 2012;69(2): 439Y46
54. Ko AH, Tabernero J, Garcia De Paredes M, et al. Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as firstYline treatment in patients (pts) with advanced cancer of the stomach (G). J Clin Oncol 2010;28(Suppl): Abstract e14575
55. Kim C, Lee JL, Choi YH, et al. Phase I doseYfinding study of sorafenib in combination with capecitabine and cisplatin as a firstYline treatment in patients with advanced gastric cancer. Invest New Drugs 2012;30(1):306Y15
56. MartinYRichard M, Gallego R, Pericay C, et al. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study. Invest New Drugs 2013;31(6):1573Y9
57. Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28(18): 2947Y51
58. Moehler M, Mueller A, Hartmann JT, et al. An openYlabel, multicentre biomarkerYoriented AIO phase II trial of sunitinib for patients with chemoYrefractory advanced gastric cancer. Eur J Cancer 2011; 47(10):1511Y20
59. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as secondYline treatment for advanced gastric cancer. Invest New Drugs 2011;29(6):1449Y58
60. Yi JH, Lee J, Lee J, et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012;106(9):1469Y74
61. GómezYMartín C, Salazar R, Montagut C, et al. A phase I, doseYfinding study of sunitinib combined with cisplatin and 5Yfluorouracil in patients with advanced gastric cancer. Invest New Drugs 2013; 31(2):390Y8
62. Wang Y, Hailey J, Williams D, et al. Inhibition of insulinYlike growth factorYI receptor (IGFYIR) signaling and tumor cell growth by a fully human neutralizing antiYIGFYIR antibody. Mol Cancer Ther 2005;4(8):1214Y21
63. Gao J, Chang YS, Jallal B, Viner J. Targeting the insulinYlike growth factor axis for the development of novel therapeutics in oncology. Cancer Res 2012;72(1):3Y12
64. Murakami H, Doi T, Yamamoto N, et al. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulinYlike growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;70(3):407Y14
65. Molife LR, Fong PC, Paccagnella L, et al. The insulinYlike growth factorYI receptor inhibitor figitumumab (CPY751,871) in combination with docetaxel in patients with advanced solid tumours: Results of a phase Ib doseYescalation, openYlabel study. Br J Cancer 2010;103(3):332Y9
66. ClinicalTrials.gov identifier: NCT01457846. Available from: Http://clinicaltrials.gov/show/ NCT01457846
67. ClinicalTrial.gov identifier: NCT01719549. Available from: Http://clinicaltrials.gov/show/ NCT01719549
68. Peruzzi B, Bottaro DP. Targeting the cYMet signaling pathway in cancer. Clin Cancer Res 2006;12(12):3657Y60
69. Janjigian YY, Tang LH, Coit DG, et al. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 2011;20(5): 1021Y7
70. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29(36):4803Y10
71. Kawakami H, Okamoto I, Arao T, et al. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget 2013;4(1):9Y17
72. Iveson T, Donehower RC, Davidenko I, et al. Safety and efficacy of epirubicin, cisplatin, and capecitabine (ECX) plus rilotumumab (R) as first line treatment for unresectable locally advanced (LA) or metastatic (M) gastric (G) or esophagogastric junction (EGJ) adenocarcinoma. Eur J Cancer 2011; 47:Suppl 1
73. Oliner KS, Tang R, Anderson A, et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 2012;30(Suppl):Abstract 4005
74. ClinicalTrials.gov identifier: NCT01697072. Available from: Http://clinicaltrials.gov/show/ NCT01697072
75. ClinicalTrials.gov identifier: NCT01662869. Available from: Http://clinicaltrials.gov/show/ NCT01662869
76. Fasolo A, Sessa C, Gianni L, Broggini M. Seminars in clinical pharmacology: An introduction to MET inhibitors for the medical oncologist. Ann Oncol 2013;24(1): 14Y20
77. Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS ONE 2013; 8(3):e54014
78. AlYBatran SE, Ducreux M, Ohtsu A. mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer 2012; 130(3):491Y6
79. Okamoto I, Doi T, Ohtsu A, et al. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 2010;40(1):17Y23
80. Werner D, Atmaca A, Pauligk C, et al. Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer Med 2013;2(3):325Y33
81. Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010;28(11):1904Y10
82. Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, DoubleYBlind, Phase III GRANITEY1 Study. J Clin Oncol 2013;31: 3935Y43
83. ClinicalTrials.gov identifier: NCT01248403. Available from: Http://clinicaltrials.gov/show/ NCT01248403
84. Wang RE. Targeting heat shock proteins 70/90 and proteasome for cancer therapy. Curr Med Chem 2011;18(27):4250Y64
85. Wang J, Cui S, Zhang X, et al. High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer. PLoS ONE 2013;8(4): E62876
86. Pick E, Kluger Y, Giltnane JM, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007;67(7):2932Y7
87. Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 2003;30(5):709Y16
88. ClinicalTrials.gov identifier: NCT01613950. Available from: Http://clinicaltrials.gov/show/ NCT01613950
89. Mani A, Gelmann EP. The ubiquitinYproteasome pathway and its role in cancer. J Clin Oncol 2005;23(21): 4776Y89
90. Fujita T, Doihara H, Washio K, et al. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs 2007;18(6):677Y86
91. Jatoi A, Dakhil SR, Foster NR, et al. Bortezomib, paclitaxel, and carboplatin as a firstYline regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: Phase II results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol 2008; 3(5):516Y20
92. Shah MA, Power DG, Kindler HL, et al. A multicenter, phase II study of bortezomib (PSY341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs 2011;29(6):1475Y81
93. Le TV, Suh JH, Kim N, Park HJ. In silico identification of poly(ADPYribose) polymeraseY1 inhibitors and their chemosensitizing effects against cisplatinYresistant human gastric cancer cells. Bioorg Med Chem Lett 2013;23(9):2642Y6
94. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modular of chemotherapyYinduced apoptosis. Cancer Res 2003;63(19):6221Y8
95. Gilardini Montani MS, Prodosmo S, Stagnis V, et al. ATMYdepletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Res 2013;32(1):95
96. Bang YJ, Im SA, Lee KW, et al. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, doubleYblind phase II study. Clin Oncol 2013;31(Suppl):Abstract 4013
97. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5(1):1Y10
98. Katsha A, Soutto M, Sehdev V, et al. Aurora kinase a promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology 2013;145(6): 1312Y22.e8
99. Sehdev V, Soutto M, Belkhiri A, et al. Effect of a combination of aurora kinase A inhibitor MNLY8237 and cisplatin on gastrointestinal tumors. J Clin Oncol 2012; 30(Suppl 4)):Abstract 58
100. Robert F, Verschraegen C, Hurwitz H, et al. A phase I trial of snsY314, a novel and selective panYaurora kinase inhibitor, in advanced solid tumor patients. J Clin Oncol 2009;27:15s (Suppl Abstract 2536
101. Arkenau HT, Plummer R, Molife LR, et al. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 2012;23(5): 1307Y13
102. Medema RH, Lin CC, Yang JC. PoloYlike kinase 1 inhibitors and their potential role in anticancer. Clin Cancer Res 2011;17(20): 6459Y66
103. Kanaji S, Saito H, Tsujitani S, et al. Expression of poloYlike kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006;70(2): 126Y33
104. Weichert W, Ullrich A, Schmidt M, et al. Expression patterns of poloYlike kinase 1 in human gastric cancer. Cancer Sci 2006; 97(4):271Y6
105. Mross K, Dittrich C, Aulitzky WE, et al. A randomised phase II trial of the PoloYlike kinase inhibitor BI 2536 in chemoYnai?ve patients with unresectable exocrine adenocarcinoma of the pancreas Y a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. Br J Cancer 2012; 107(2):280Y6
106. Hofheinz RD, AlYBatran SE, Hochhaus A, et al. An openYlabel, phase I study of the poloYlike kinaseY1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 2010;16(18):4666Y74
107. Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclinYdependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001;19(7):1985Y92
108. Rathkopf D, Dickson MA, Feldman DR, et al. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res 2009;15(23):7405Y11
109. ClinicalTrials.gov identifier: NCT00991952. Available from: Http://clinicaltrials.gov/show/ NCT00991952
110. Janjigian YY, Tang LH, Shibata S, et al. A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wildYtype gastric adenocarcinoma (NCI 8060). J Clin Oncol 2012;30(Suppl)): Abstract e14586
111. AlYBatran SE, Pauligk C, Wirtz R, et al. The validation of matrix metalloproteinaseY9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Ann Oncol 2012; 23(7):1699Y705
112. Ahn GO, Brown JM. Matrix metalloproteinaseY9 is required for tumor vasculogenesis but not for angiogenesis: Role of bone marrowYderived myelomonocytic cells. Cancer Cell 2008;13(3):193Y205
113. Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular endothelial growth factor receptorY1 is involved in lungYspecific metastasis. Cancer Cell 2002; 2(4):289Y300
114. Bramhall SR, Hallissey MT, Whiting J, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial. Br J Cancer 2002; 86(12):1864Y70
115. Cheng J, Fan XM. Role of cyclooxygenaseY2 in gastric cancer development and progression. World J Gastroenterol 2013;19(42):7361Y8
116. Sahin IH, Hassan MM, Garrett CR. Impact of nonYsteroidal antiYinflammatory drugs on gastrointestinal cancers: Current stateYofYthe science. Cancer Lett 2013. [Epub ahead of print]
117. Wong BC, Zhang L, Ma JL, et al. Effects of selective COXY2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012; 61(6):812Y18
118. Wang WH, Huang JQ, Zheng GF, et al. NonYsteroidal antiYinflammatory drug use and the risk of gastric cancer: A systematic review and metaYanalysis. J Natl Cancer Inst 2003;95(23):1784Y91
119. Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Aspirin protects against gastric cancer: Results of a caseYcontrol study from Moscow, Russia. Int J Cancer 1999; 82(4):473Y6
120. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993;53(6):1322Y7
121. Altorki NK, Christos P, Port JL, et al. Preoperative taxaneYbased chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: Results of a phase 2 trial. J Thorac Oncol 2011;6(6): 1121Y7
122. Toomey PG, Vohra NA, Ghansah T, et al. Immunotherapy for gastrointestinal malignancies. Cancer Control 2013;20(1): 32Y42
123. Jäger M, Schoberth A, Ruf P, et al. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res 2009;69(10):4270Y6
124. ClinicalTrials.gov identifier: NCT01569412. Available from: Http://clinicaltrials.gov/show/ NCT01569412
125. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010;127(9):2209Y21
126. Türeci O, Koslowski M, Helftenbein G, et al. ClaudinY18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene 2011;481(2):83Y92
127. Sahin U, Koslowski M, Dhaene K, et al. ClaudinY18 splice variant 2 is a panYcancer target suitable for therapeutic antibody development. Clin Cancer Res 2008;14(23): 7624Y34
128. ClinicalTrials.gov identifier: NCT01630083. Available from: Http://clinicaltrials.gov/show/ NCT01630083
129. Schuler MH, Zvirbule Z, Lordick F, et al. Safety, tolerability, and efficacy of the firstYinYclass antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas. J Clin Oncol 2013;31:Suppl Abstract 4080
130. Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokineYinduced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 2012;61(12):2251Y9
131. Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HERY2/neuderived peptides can induce specific TYcell responses in patients with gastric cancer. Clin Cancer Res 2002;8(11):3394Y400
132. Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol 2009;15(1):1Y16
133. ClinicalTrials.gov identifier: NCT00020787. Available from: Http://clinicaltrials.gov/show/ NCT00020787
134. Lei Z, Tan IB, Das K, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3Ykinase inhibitors and 5Yfluorouracil. Gastroenterology 2013; 145(3):554Y65.